Company profile CUE

Cue Biopharma Inc
Description of the company is not available.
Quarter analysis & expected interestLast update: February 08 2024 19:40:19.

After 39 days of this quarter the interest is at 37.0. Based on that we can calculate that during remaining 52 days it will total up to 86.0.
Cue Biopharma expected interest is significantly lower compared to previous quarter (-77.2%) and same quarter last year (-52.7%).

YearQ1Q2Q3Q4
2019135
323
139.3% QoQ
97
-70.0% QoQ
171
76.3% QoQ
2020 440
225.9% YoY 157.3% QoQ
392
21.4% YoY -10.9% QoQ
158
62.9% YoY -59.7% QoQ
245
43.3% YoY 55.1% QoQ
2021 207
-53.0% YoY -15.5% QoQ
267
-31.9% YoY 29.0% QoQ
421
166.5% YoY 57.7% QoQ
209
-14.7% YoY -50.4% QoQ
2022 181
-12.6% YoY -13.4% QoQ
142
-46.8% YoY -21.5% QoQ
328
-22.1% YoY 131.0% QoQ
159
-23.9% YoY -51.5% QoQ
2023 182
0.6% YoY 14.5% QoQ
127
-10.6% YoY -30.2% QoQ
297
-9.5% YoY 133.9% QoQ
377
137.1% YoY 26.9% QoQ
2024 37
-79.7% YoY -90.2% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Cue Biopharma search interestLast update: February 08 2024 19:40:18.
Correlation coefficient between keyword and revenue is 0.08
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 19:40:19.

The average 5 years interest of Cue Biopharma was 18.75 per week.
The last year interest of Cue Biopharma compared to the last 5 years has changed by 2.99%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 15.84%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for CUE-101 clinical trial to provide analysis

Correlation between past revenue and CUE-101 clinical trial search interest

There is not enough data for CUE-101 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for CUE-101 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 04 2023 01:26:46.

After 34 days of this quarter the interest is at 310.0. Based on that we can calculate that during remaining 58 days it will total up to 839.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2018 - - - 493
2019 730
48.1% QoQ
709
-2.9% QoQ
661
-6.8% QoQ
658
33.5% YoY -0.5% QoQ
2020 690
-5.5% YoY 4.9% QoQ
578
-18.5% YoY -16.2% QoQ
604
-8.6% YoY 4.5% QoQ
559
-15.0% YoY -7.5% QoQ
2021 610
-11.6% YoY 9.1% QoQ
635
9.9% YoY 4.1% QoQ
626
3.6% YoY -1.4% QoQ
670
19.9% YoY 7.0% QoQ
2022 764
25.2% YoY 14.0% QoQ
843
32.8% YoY 10.3% QoQ
769
22.8% YoY -8.8% QoQ
735
9.7% YoY -4.4% QoQ
2023 827
8.2% YoY 12.5% QoQ
806
-4.4% YoY -2.5% QoQ
785
2.1% YoY -2.6% QoQ
310
-57.8% YoY -60.5% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Cancer immunotherapy search interestLast update: November 04 2023 01:26:45.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 04 2023 01:26:46.

The average 5 years interest of Cancer immunotherapy was 53.88 per week.
The last year interest of Cancer immunotherapy compared to the last 5 years has changed by 12.75%.
The interest for Cancer immunotherapy is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by 12.46%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 19:40:25.

After 39 days of this quarter the interest is at 293.0. Based on that we can calculate that during remaining 52 days it will total up to 684.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019327
623
90.5% QoQ
482
-22.6% QoQ
492
2.1% QoQ
2020 637
94.8% YoY 29.5% QoQ
528
-15.2% YoY -17.1% QoQ
533
10.6% YoY 0.9% QoQ
593
20.5% YoY 11.3% QoQ
2021 590
-7.4% YoY -0.5% QoQ
631
19.5% YoY 6.9% QoQ
710
33.2% YoY 12.5% QoQ
482
-18.7% YoY -32.1% QoQ
2022 727
23.2% YoY 50.8% QoQ
661
4.8% YoY -9.1% QoQ
730
2.8% YoY 10.4% QoQ
705
46.3% YoY -3.4% QoQ
2023 860
18.3% YoY 22.0% QoQ
909
37.5% YoY 5.7% QoQ
798
9.3% YoY -12.2% QoQ
890
26.2% YoY 11.5% QoQ
2024 293
-65.9% YoY -67.1% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Autoimmune disease treatment search interestLast update: February 08 2024 19:40:24.
Correlation coefficient between keyword and revenue is -0.22
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 19:40:26.

The average 5 years interest of Autoimmune disease treatment was 50.58 per week.
The last year interest of Autoimmune disease treatment compared to the last 5 years has changed by 28.67%.
The interest for Autoimmune disease treatment is trending.
The last year interest is quite higher compared to 5 years ago. It has increased by 56.37%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 05 2023 05:01:09.

After 34 days of this quarter the interest is at 49.0. Based on that we can calculate that during remaining 58 days it will total up to 133.0.
Biologics development expected interest is significantly lower compared to same quarter last year (-58.0%) but similar to previous quarter.

YearQ1Q2Q3Q4
2018 - - - 59
2019 265
349.2% QoQ
0
-100.0% QoQ
260
inf% QoQ
130
120.3% YoY -50.0% QoQ
2020 166
-37.4% YoY 27.7% QoQ
200
inf% YoY 20.5% QoQ
261
0.4% YoY 30.5% QoQ
89
-31.5% YoY -65.9% QoQ
2021 80
-51.8% YoY -10.1% QoQ
144
-28.0% YoY 80.0% QoQ
122
-53.3% YoY -15.3% QoQ
210
136.0% YoY 72.1% QoQ
2022 244
205.0% YoY 16.2% QoQ
171
18.8% YoY -29.9% QoQ
383
213.9% YoY 124.0% QoQ
317
51.0% YoY -17.2% QoQ
2023 154
-36.9% YoY -51.4% QoQ
278
62.6% YoY 80.5% QoQ
198
-48.3% YoY -28.8% QoQ
49
-84.5% YoY -75.3% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Biologics development search interestLast update: November 05 2023 05:01:09.
Correlation coefficient between keyword and revenue is -0.07
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 05 2023 05:01:11.

The average 5 years interest of Biologics development was 14.54 per week.
The last year interest of Biologics development compared to the last 5 years has changed by 14.65%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 40.32%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Tumor-specific T cells to provide analysis

Correlation between past revenue and Tumor-specific T cells search interest

There is not enough data for Tumor-specific T cells to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Tumor-specific T cells to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Cue Biopharma stock price to provide analysis

Correlation between past revenue and Cue Biopharma stock price search interest

There is not enough data for Cue Biopharma stock price to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Cue Biopharma stock price to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Cue Biopharma Boston to provide analysis

Correlation between past revenue and Cue Biopharma Boston search interest

There is not enough data for Cue Biopharma Boston to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Cue Biopharma Boston to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: October 09 2023 08:19:26.

After 92 days of this quarter the interest is at 36.0. Based on that we can calculate that during remaining 0 days it will total up to 36.0.
Cue Biopharma -stock -company expected interest is significantly lower compared to previous quarter (-79.4%) and same quarter last year (-58.1%).

YearQ1Q2Q3Q4
2018 - - - 137
2019 363
165.0% QoQ
197
-45.7% QoQ
394
100.0% QoQ
156
13.9% YoY -60.4% QoQ
2020 149
-59.0% YoY -4.5% QoQ
299
51.8% YoY 100.7% QoQ
305
-22.6% YoY 2.0% QoQ
118
-24.4% YoY -61.3% QoQ
2021 134
-10.1% YoY 13.6% QoQ
326
9.0% YoY 143.3% QoQ
212
-30.5% YoY -35.0% QoQ
198
67.8% YoY -6.6% QoQ
2022 255
90.3% YoY 28.8% QoQ
170
-47.9% YoY -33.3% QoQ
86
-59.4% YoY -49.4% QoQ
142
-28.3% YoY 65.1% QoQ
2023 195
-23.5% YoY 37.3% QoQ
175
2.9% YoY -10.3% QoQ
36
-58.1% YoY -79.4% QoQ
0
-100.0% YoY -100.0% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Cue Biopharma -stock -company search interestLast update: October 09 2023 08:19:26.
Correlation coefficient between keyword and revenue is 0.09
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: October 09 2023 08:19:26.

The average 5 years interest of Cue Biopharma -stock -company was 15.57 per week.
The last year interest of Cue Biopharma -stock -company compared to the last 5 years has changed by -32.31%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -49.76%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for CUE
Earnings date: 2024-03-19 After close
Company name: Cue Biopharma Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T20:07:28Z

GlobeNewswire
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments

2026-05-07T23:07:21Z

GlobeNewswire
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-04-30T20:25:00Z

GlobeNewswire
Cue Biopharma Announces $30 Million Private Placement

2026-04-30T20:15:00Z

GlobeNewswire
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

2026-04-30T20:05:00Z

GlobeNewswire
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

2026-04-22T12:37:18Z

GlobeNewswire
Cue Biopharma Announces 1-for-30 Reverse Stock Split

2026-04-15T12:00:00Z

GlobeNewswire
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026

2026-04-08T12:00:00Z

GlobeNewswire
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

2026-03-27T20:05:00Z

GlobeNewswire
Cue Biopharma Announces CEO Transition

2026-03-26T12:00:00Z

GlobeNewswire
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

2026-03-16T20:05:00Z

GlobeNewswire
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

2026-03-09T12:00:00Z

GlobeNewswire
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

2026-02-17T13:00:00Z

GlobeNewswire
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

2026-02-12T13:00:00Z

GlobeNewswire
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

2025-12-19T13:00:00Z

GlobeNewswire
Cue Biopharma Announces Pricing of $10 Million Public Offering